Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Non-coding RNAs in Lung Cancer Chemoresistance

Author(s): Priya Mondal, Jagadish Natesh, Mohammad Amjad Kamal and Syed Musthapa Meeran*

Volume 20, Issue 13, 2019

Page: [1023 - 1032] Pages: 10

DOI: 10.2174/1389200221666200106105201

Price: $65

Abstract

Background: Lung cancer is the leading cause of cancer-associated death worldwide with limited treatment options. The major available treatment options are surgery, radiotherapy, chemotherapy and combinations of these treatments. In chemotherapy, tyrosine kinase inhibitors and taxol are the first lines of chemotherapeutics used for the treatment of lung cancer. Often drug resistance in the clinical settings hinders the efficiency of the treatment and intrigues the tumor relapse. Drug-resistance is triggered either by intrinsic factors or due to the prolonged cycles of chemotherapy as an acquired-resistance. There is an emerging role of non-coding RNAs (ncRNAs), including notorious microRNAs (miRNAs), proposed to be actively involved in the regulations of various tumor-suppressor genes and oncogenes.

Results: The altered gene expression by miRNA is largely mediated either by the degradation or by interfering with the translation of targeted mRNA. Unlike miRNA, other type of ncRNAs, such as long non-coding RNAs (lncRNAs), can target the transcriptional activator or the repressor, RNA polymerase, and even DNA-duplex to regulate the gene expressions. Many studies have confirmed the crucial role of ncRNAs in lung adenocarcinoma progression and importantly, in the acquisition of chemoresistance. Recently, ncRNAs have become early biomarkers and therapeutic targets for lung cancer.

Conclusion: Targeting ncRNAs could be an effective approach for the development of novel therapeutics against lung cancer and to overcome the chemoresistance.

Keywords: Non-coding RNA, microRNA, chemoresistance, drug-resistance, long non-coding RNA, tyrosine kinase inhibitor, Taxol.

« Previous Next »
Graphical Abstract

[1]
de Groot, P.M.; Wu, C.C.; Carter, B.W.; Munden, R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res., 2018, 7(3), 220.
[http://dx.doi.org/10.21037/tlcr.2018.05.06]
[2]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[http://dx.doi.org/10.3322/caac.21442]
[3]
Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A.S.; Kong, D.; Banerjee, S.; Sarkar, F.H. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat., 2010, 13(4-5), 109-118.
[http://dx.doi.org/10.1016/j.drup.2010.07.001]
[4]
Ayers, D.; Vandesompele, J. Influence of microRNAs and long non-coding RNAs in cancer chemoresistance. Genes (Basel), 2017, 8(3), 95.
[http://dx.doi.org/10.3390/genes8030095]
[5]
Gutschner, T.; Diederichs, S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol., 2012, 9(6), 703-719.
[http://dx.doi.org/10.4161/rna.20481]
[6]
Berindan-Neagoe, I.; Braicu, C.; Gulei, D.; Tomuleasa, C.; Calin, G.A. Noncoding RNAs in lung cancer angiogenesis In: Physiologic and Pathologic Angiogenesis-Signaling Mechanisms and Targeted Therapy;Dan Simionescu, and agneta Simionescu, Ed.;; IntechOpen: Croatia,. , 2017; pp. 251-289.
[http://dx.doi.org/10.5772/66529]
[7]
Xu, N.; Chen, S.; Liu, Y.; Li, W.; Liu, Z.; Bian, X.; Ling, C.; Jiang, M. Profiles and bioinformatics analysis of differentially expressed circrnas in Taxol-resistant non-small cell lung cancer cells. Cell. Physiol. Biochem., 2018, 48(5), 2046-2060.
[http://dx.doi.org/10.1159/000492543]
[8]
Taft, R.J.; Pang, K.C.; Mercer, T.R.; Dinger, M.; Mattick, J.S. Non‐coding RNAs: regulators of disease. J. Pathol., 2010, 220(2), 126-139.
[http://dx.doi.org/10.1002/path.2638]
[9]
Ma, L.; Bajic, V.B.; Zhang, Z. On the classification of long non-coding RNAs. RNA Biol., 2013, 10(6), 925-933.
[http://dx.doi.org/10.4161/rna.24604]
[10]
Mattick, J.S.; Makunin, I.V. Non-coding RNA Hum. Mol. Genet, 2006, 15(1), R17-R29.l.
[11]
Martin, S.L.; Royston, K.J.; Tollefsbol, T.O. The role of non-coding rnas and isothiocyanates in cancer. Mol. Nutr. Food Res., 2018, 62(18)e1700913
[http://dx.doi.org/10.1002/mnfr.201700913]
[12]
Donzelli, S.; Mori, F.; Biagioni, F.; Bellissimo, T.; Pulito, C.; Muti, P.; Strano, S.; Blandino, G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol. Cell. Ther., 2014, 2(1), 16.
[http://dx.doi.org/10.1186/2052-8426-2-16]
[13]
Garzon, R.; Fabbri, M.; Cimmino, A.; Calin, G.A.; Croce, C.M. MicroRNA expression and function in cancer. Trends Mol. Med., 2006, 12(12), 580-587.
[http://dx.doi.org/10.1016/j.molmed.2006.10.006]
[14]
Cai, Y.; Yu, X.; Hu, S.; Yu, J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics, 2009, 7(4), 147-154.
[http://dx.doi.org/10.1016/S1672-0229(08)60044-3]
[15]
Lin, P.; Yu, S.; Yang, P. MicroRNA in lung cancer. Br. J. Cancer, 2010, 103(8), 1144.
[http://dx.doi.org/10.1038/sj.bjc.6605901]
[16]
Adams, B.D.; Kasinski, A.L.; Slack, F.J. Aberrant regulation and function of microRNAs in cancer. Curr. Biol., 2014, 24(16), R762-R776.
[http://dx.doi.org/10.1016/j.cub.2014.06.043]
[17]
MacDonagh, L.; Gray, S.G.; Finn, S.P.; Cuffe, S.; O’Byrne, K.J.; Barr, M.P. The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treat. Rev., 2015, 41(2), 160-169.
[http://dx.doi.org/10.1016/j.ctrv.2014.12.009]
[18]
Jha, A.; Mehra, M.; Shankar, R. The regulatory epicenter of miRNAs. J. Biosci., 2011, 36(4), 621-638.
[http://dx.doi.org/10.1007/s12038-011-9109-y]
[19]
Jansson, M.D.; Lund, A.H. MicroRNA and cancer. Mol. Oncol., 2012, 6(6), 590-610.
[http://dx.doi.org/10.1016/j.molonc.2012.09.006]
[20]
Price, C.; Chen, J. MicroRNAs in cancer biology and therapy: Current status and perspectives. Genes Dis., 2014, 1(1), 53-63.
[http://dx.doi.org/10.1016/j.gendis.2014.06.004]
[21]
Chatterjee, A.; Chattopadhyay, D.; Chakrabarti, G. miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS One, 2014, 9(4)e95716
[http://dx.doi.org/10.1371/journal.pone.0095716]
[22]
Goncalves, A.; Braguer, D.; Kamath, K.; Martello, L.; Briand, C.; Horwitz, S.; Wilson, L.; Jordan, M.A. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. USA, 2001, 98(20), 11737-11742.
[http://dx.doi.org/10.1073/pnas.191388598]
[23]
Cui, S.Y.; Wang, R.; Chen, L.B. MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J. Cell. Mol. Med., 2013, 17(10), 1207-1217.
[http://dx.doi.org/10.1111/jcmm.12131]
[24]
Sève, P.; Dumontet, C. Chemoresistance in non-small cell lung cancer. Curr. Med. Chem. Anticancer Agents, 2005, 5(1), 73-88.
[http://dx.doi.org/10.2174/1568011053352604]
[25]
Yu, X.; Zhang, Y.; Ma, X.; Pertsemlidis, A. miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett., 2018, 427, 85-93.
[http://dx.doi.org/10.1016/j.canlet.2018.04.007]
[26]
Du, L.; Subauste, M.C.; DeSevo, C.; Zhao, Z.; Baker, M.; Borkowski, R.; Schageman, J.J.; Greer, R.; Yang, C.R.; Suraokar, M. Wistuba, II; Gazdar, A. F.; Minna, J. D.; Pertsemlidis, A. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One, 2012, 7(6)e39167
[http://dx.doi.org/10.1371/journal.pone.0039167]
[27]
Xu, X.; Jin, S.; Ma, Y.; Fan, Z.; Yan, Z.; Li, W.; Song, Q.; You, W.; Lyu, Z.; Song, Y.; Shi, P.; Liu, Y.; Han, X.; Li, L.; Li, Y.; Ye, Q. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J. Mol. Med. (Berl.), 2017, 95(8), 861-871.
[http://dx.doi.org/10.1007/s00109-017-1539-z]
[28]
Lu, C.; Xie, Z.; Peng, Q. MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am. J. Cancer Res., 2017, 7(9), 1863.
[29]
Catuogno, S.; Cerchia, L.; Romano, G.; Pognonec, P.; Condorelli, G.; de Franciscis, V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene, 2013, 32(3), 341-351.
[http://dx.doi.org/10.1038/onc.2012.51]
[30]
Liu, R.; Liu, X.; Zheng, Y.; Gu, J.; Xiong, S.; Jiang, P.; Jiang, X.; Huang, E.; Yang, Y.; Ge, D.; Chu, Y. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol. Lett., 2014, 8(5), 2193-2200.
[http://dx.doi.org/10.3892/ol.2014.2500]
[31]
Holleman, A.; Chung, I.; Olsen, R.R.; Kwak, B.; Mizokami, A.; Saijo, N.; Parissenti, A.; Duan, Z.; Voest, E.E.; Zetter, B.R. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene, 2011, 30(43), 4386-4398.
[http://dx.doi.org/10.1038/onc.2011.148]
[32]
Zhang, J-g.; Guo, J-F.; Liu, D-L.; Liu, Q.; Wang, J-J. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J. Thorac. Oncol., 2011, 6(4), 671-678.
[http://dx.doi.org/10.1097/JTO.0b013e318208eb35]
[33]
Zhu, X.; Li, H.; Long, L.; Hui, L.; Chen, H.; Wang, X.; Shen, H.; Xu, W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim. Biophys. Sin. (Shanghai), 2012, 44(6), 519-526.
[http://dx.doi.org/10.1093/abbs/gms026]
[34]
Koh, H.; Park, H.; Chandimali, N.; Huynh, D.L.; Zhang, J.J.; Ghosh, M.; Gera, M.; Kim, N.; Bak, Y.; Yoon, D-Y. MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget, 2017, 8(66)110540
[http://dx.doi.org/10.18632/oncotarget.22818]
[35]
Feng, B.; Wang, R.; Chen, L.B. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett., 2012, 317(2), 184-191.
[http://dx.doi.org/10.1016/j.canlet.2011.11.024]
[36]
Cao, J.; Geng, J.; Chu, X.; Wang, R.; Huang, G.; Chen, L. miRNA8853p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A. Oncol. Rep., 2019, 41(2), 1218-1230.
[37]
Feng, B.; Wang, R.; Song, H.Z.; Chen, L.B. MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer, 2012, 118(13), 3365-3376.
[http://dx.doi.org/10.1002/cncr.26560]
[38]
Pan, B.; Feng, B.; Chen, Y.; Huang, G.; Wang, R.; Chen, L.; Song, H. MiR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma. Oncotarget, 2015, 6(32), 32805.
[http://dx.doi.org/10.18632/oncotarget.5352]
[39]
Huang, J-Y.; Cui, S-Y.; Chen, Y-T.; Song, H-Z.; Huang, G-C.; Feng, B.; Sun, M.; De, W.; Wang, R.; Chen, L-B. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One, 2013, 8(8)e72615
[http://dx.doi.org/10.1371/journal.pone.0072615]
[40]
Wang, D.; Ma, J.; Ji, X.; Xu, F.; Wei, Y. miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer. Oncol. Rep., 2017, 37(1), 608-616.
[http://dx.doi.org/10.3892/or.2016.5214]
[41]
Cui, S.Y.; Huang, J.Y.; Chen, Y.T.; Song, H.Z.; Feng, B.; Huang, G.C.; Wang, R.; Chen, L.B.; De, W. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma. Mol. Cancer Res., 2013, 11(7), 699-713.
[http://dx.doi.org/10.1158/1541-7786.MCR-13-0019-T]
[42]
Huang, J.; Chen, Y.; Li, J.; Zhang, K.; Chen, J.; Chen, D.; Feng, B.; Song, H.; Feng, J.; Wang, R.; Chen, L. Notch-1 Confers chemoresistance in lung adenocarcinoma to taxanes through ap-1/microrna-451 mediated regulation of MDR-1. Mol. Ther. Nucleic Acids, 2016, 5(10)e375
[http://dx.doi.org/10.1038/mtna.2016.82]
[43]
Chen, D.; Huang, J.; Zhang, K.; Pan, B.; Chen, J.; De, W.; Wang, R.; Chen, L. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur. J. Cancer, 2014, 50(17), 3050-3067.
[http://dx.doi.org/10.1016/j.ejca.2014.09.008]
[44]
Chen, J.; Xu, Y.; Tao, L.; Pan, Y.; Zhang, K.; Wang, R.; Chen, L.B.; Chu, X. MiRNA-26a Contributes to the acquisition of malignant behaviors of doctaxel-resistant lung adenocarcinoma cells through targeting ezh2. Cell. Physiol. Biochem., 2017, 41(2), 583-597.
[http://dx.doi.org/10.1159/000457879]
[45]
Bartholomew, C.; Eastlake, L.; Dunn, P.; Yiannakis, D. EGFR targeted therapy in lung cancer; an evolving story. Respir. Med. Case Rep., 2017, 20, 137-140.
[http://dx.doi.org/10.1016/j.rmcr.2017.01.016]
[46]
Riely, G.J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J. Thorac. Oncol., 2008, 3(6), S146-S149.
[http://dx.doi.org/10.1097/JTO.0b013e318174e96e]
[47]
Sequist, L.V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist, 2007, 12(3), 325-330.
[http://dx.doi.org/10.1634/theoncologist.12-3-325]
[48]
Steuer, C.E.; Khuri, F.R.; Ramalingam, S.S. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer, 2015, 121(8), E1-E6.
[http://dx.doi.org/10.1002/cncr.29139]
[49]
Ou, S-H.I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol., 2012, 83(3), 407-421.
[http://dx.doi.org/10.1016/j.critrevonc.2011.11.010]
[50]
Wang, S.; Cang, S.; Liu, D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J. Hematol. Oncol., 2016, 9(1), 34.
[http://dx.doi.org/10.1186/s13045-016-0268-z]
[51]
Ma, W.; Kang, Y.; Ning, L.; Tan, J.; Wang, H.; Ying, Y. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway. Exp. Ther. Med., 2017, 14(4), 2853-2862.
[http://dx.doi.org/10.3892/etm.2017.4847]
[52]
Lee, C.G.; McCarthy, S.; Gruidl, M.; Timme, C.; Yeatman, T.J. MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance. PLoS One, 2014, 9(1)e84597
[http://dx.doi.org/10.1371/journal.pone.0084597]
[53]
Magee, P.; Shi, L.; Garofalo, M. Role of microRNAs in chemoresistance. Ann. Transl. Med., 2015, 3(21), 332.
[54]
Han, F.; He, J.; Li, F.; Yang, J.; Wei, J.; Cho, W.C.; Liu, X. Emerging roles of microRNAs in EGFR-targeted therapies for lung cancer. BioMed Res. Int., 2015, 2015672759
[http://dx.doi.org/10.1155/2015/672759]
[55]
Kunz, M.; Gottlich, C.; Walles, T.; Nietzer, S.; Dandekar, G.; Dandekar, T. MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumour Biol., 2017, 39(7)1010428317706430
[http://dx.doi.org/10.1177/1010428317706430]
[56]
Xie, M.; Ma, L.; Xu, T.; Pan, Y.; Wang, Q.; Wei, Y.; Shu, Y. Potential regulatory roles of microRNAs and long noncoding RNAs in anticancer therapies. Mol. Ther. Nucleic Acids, 2018, 13, 233-243.
[http://dx.doi.org/10.1016/j.omtn.2018.08.019]
[57]
Shen, H.; Zhu, F.; Liu, J.; Xu, T.; Pei, D.; Wang, R.; Qian, Y.; Li, Q.; Wang, L.; Shi, Z.; Zheng, J.; Chen, Q.; Jiang, B.; Shu, Y. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One, 2014, 9(7)e103305
[http://dx.doi.org/10.1371/journal.pone.0103305]
[58]
Wang, Y.S.; Wang, Y.H.; Xia, H.P.; Zhou, S.W.; Schmid-Bindert, G.; Zhou, C.C. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev., 2012, 13(1), 255-260.
[http://dx.doi.org/10.7314/APJCP.2012.13.1.255]
[59]
Kitamura, K.; Seike, M.; Okano, T.; Matsuda, K.; Miyanaga, A.; Mizutani, H.; Noro, R.; Minegishi, Y.; Kubota, K.; Gemma, A. MiR-134/487b/655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol. Cancer Ther., 2014, 13(2), 444-453.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0448]
[60]
Zhou, J.Y.; Chen, X.; Zhao, J.; Bao, Z.; Zhang, P.; Liu, Z.F. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett., 2014, 351(2), 265-271.
[http://dx.doi.org/10.1016/j.canlet.2014.06.010]
[61]
Mataki, H.; Seki, N.; Chiyomaru, T.; Enokida, H.; Goto, Y.; Kumamoto, T.; Machida, K.; Mizuno, K.; Nakagawa, M.; Inoue, H. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. Int. J. Oncol., 2015, 46(3), 1039-1050.
[http://dx.doi.org/10.3892/ijo.2014.2802]
[62]
Jiao, D.; Chen, J.; Li, Y.; Tang, X.; Wang, J.; Xu, W.; Song, J.; Tao, H.; Chen, Q. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J. Cell. Mol. Med., 2018, 22(7), 3526-3536.
[http://dx.doi.org/10.1111/jcmm.13629]
[63]
Ma, W.; Feng, W.; Tan, J.; Xu, A.; Hu, Y.; Ning, L.; Kang, Y.; Wang, L.; Zhao, Z. miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor. J. Thorac. Dis., 2018, 10(10), 5889-5897.
[http://dx.doi.org/10.21037/jtd.2018.10.40]
[64]
Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S-S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6), 498-509.
[http://dx.doi.org/10.1016/j.ccr.2009.10.014]
[65]
Ricciuti, B.; Mecca, C.; Cenci, M.; Leonardi, G.C.; Perrone, L.; Mencaroni, C.; Crino, L.; Grignani, F.; Baglivo, S.; Chiari, R.; Sidoni, A.; Paglialunga, L.; Curra, M.F.; Murano, E.; Minotti, V.; Metro, G. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance. Ecancermedicalscience, 2015, 9, 569.
[http://dx.doi.org/10.3332/ecancer.2015.569]
[66]
Sin, T.K.; Wang, F.; Meng, F.; Wong, S.C.; Cho, W.C.; Siu, P.M.; Chan, L.W.; Yung, B.Y. Implications of MicroRNAs in the treatment of gefitinib-resistant non-small cell lung cancer. Int. J. Mol. Sci., 2016, 17(2), 237.
[http://dx.doi.org/10.3390/ijms17020237]
[67]
Baumgartner, U.; Berger, F.; Hashemi Gheinani, A.; Burgener, S.S.; Monastyrskaya, K.; Vassella, E. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer. Mol. Cancer, 2018, 17(1), 44.
[http://dx.doi.org/10.1186/s12943-018-0781-5]
[68]
Gao, Y.; Fan, X.; Li, W.; Ping, W.; Deng, Y.; Fu, X. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem. Biophys. Res. Commun., 2014, 446(1), 179-186.
[http://dx.doi.org/10.1016/j.bbrc.2014.02.073]
[69]
Wang, Y.; Xia, H.; Zhuang, Z.; Miao, L.; Chen, X.; Cai, H. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell Death Dis.,, 2014, 5e1227.
[http://dx.doi.org/10.1038/cddis.2014.186]
[70]
Wu, D.W.; Wang, Y.C.; Wang, L.; Chen, C.Y.; Lee, H. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics, 2018, 8(5), 1256-1269.
[http://dx.doi.org/10.7150/thno.22048]
[71]
Ping, W.; Gao, Y.; Fan, X.; Li, W.; Deng, Y.; Fu, X. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7. Biochem. Biophys. Res. Commun., 2018, 495(4), 2482-2489.
[http://dx.doi.org/10.1016/j.bbrc.2017.12.096]
[72]
Rai, K.; Takigawa, N.; Ito, S.; Kashihara, H.; Ichihara, E.; Yasuda, T.; Shimizu, K.; Tanimoto, M.; Kiura, K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther., 2011, 10(9), 1720-1727.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0220]
[73]
Zhen, Q.; Liu, J.; Gao, L.; Wang, R.; Chu, W.; Zhang, Y.; Tan, G.; Zhao, X.; Lv, B. MicroRNA-200a Targets EGFR and c-Met to inhibit migration, invasion, and gefitinib resistance in non-small cell lung cancer. Cytogenet. Genome Res., 2015, 146(1), 1-8.
[http://dx.doi.org/10.1159/000434741]
[74]
Yin, J.; Hu, W.; Pan, L.; Fu, W.; Dai, L.; Jiang, Z.; Zhang, F.; Zhao, J. let7 and miR17 promote selfrenewal and drive gefitinib resistance in nonsmall cell lung cancer. Oncol. Rep., 2019, 42(2), 495-508.
[75]
Yue, J.; Lv, D.; Wang, C.; Li, L.; Zhao, Q.; Chen, H.; Xu, L. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene, 2018, 37(31), 4300-4312.
[http://dx.doi.org/10.1038/s41388-018-0276-2]
[76]
Ning, Z-Q.; Lu, H-l.; Chen, C.; Wang, L.; Cai, W.; Li, Y.; Cao, T-H.; Zhu, J.; Shu, Y-Q.; Shen, H. MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma. Oncotarget, 2017, 8(3), 4572.
[http://dx.doi.org/10.18632/oncotarget.13944]
[77]
Wang, N.; Zhang, T. Downregulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16. Oncol. Res., 2018, 26(7), 1005-1014.
[http://dx.doi.org/10.3727/096504017X15144755633680]
[78]
Hojbjerg, J.A.; Ebert, E.B.F.; Clement, M.S.; Winther-Larsen, A.; Meldgaard, P.; Sorensen, B. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer, 2019, 135, 92-96.
[http://dx.doi.org/10.1016/j.lungcan.2019.07.005]
[79]
Gibb, E.A.; Brown, C.J.; Lam, W.L. The functional role of long non-coding RNA in human carcinomas. Mol. Cancer, 2011, 10(1), 38.
[http://dx.doi.org/10.1186/1476-4598-10-38]
[80]
Ren, K.; Xu, R.; Huang, J.; Zhao, J.; Shi, W. Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma. Cancer Chemother. Pharmacol., 2017, 80(2), 243-250.
[http://dx.doi.org/10.1007/s00280-017-3356-z]
[81]
Wang, P.; Chen, D.; Ma, H.; Li, Y. LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer. Oncotarget, 2017, 8(48), 84086.
[http://dx.doi.org/10.18632/oncotarget.20475]
[82]
Xu, R.; Mao, Y.; Chen, K.; He, W.; Shi, W.; Han, Y. The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells. Oncotarget, 2017, 8(24), 39177.
[http://dx.doi.org/10.18632/oncotarget.16640]
[83]
Chen, J.; Zhang, K.; Song, H.; Wang, R.; Chu, X.; Chen, L. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget, 2016, 7(38), 62474.
[http://dx.doi.org/10.18632/oncotarget.11518]
[84]
Pan, H.; Jiang, T.; Cheng, N.; Wang, Q.; Ren, S.; Li, X.; Zhao, C.; Zhang, L.; Cai, W.; Zhou, C. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget, 2016, 7(31), 49948.
[http://dx.doi.org/10.18632/oncotarget.10521]
[85]
Cheng, N.; Cai, W.; Ren, S.; Li, X.; Wang, Q.; Pan, H.; Zhao, M.; Li, J.; Zhang, Y.; Zhao, C. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget, 2015, 6(27), 23582.
[http://dx.doi.org/10.18632/oncotarget.4361]
[86]
Cheng, N.; Li, X.; Zhao, C.; Ren, S.; Chen, X.; Cai, W.; Zhao, M.; Zhang, Y.; Li, J.; Wang, Q. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol. Rep., 2015, 33(2), 833-839.
[http://dx.doi.org/10.3892/or.2014.3643]
[87]
Fu, Y.; Li, C.; Luo, Y.; Li, L.; Liu, J.; Gui, R. Silencing of long non-coding RNA MIAT sensitizes lung cancer cells to gefitinib by epigenetically regulating miR-34a. Front. Pharmacol., 2018, 9, 82.
[http://dx.doi.org/10.3389/fphar.2018.00082]
[88]
Gallardo, E.; Navarro, A.; Viñolas, N.; Marrades, R.M.; Diaz, T.; Gel, B.; Quera, A.; Bandres, E.; Garcia-Foncillas, J.; Ramirez, J. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis, 2009, 30(11), 1903-1909.
[http://dx.doi.org/10.1093/carcin/bgp219]
[89]
Wang, B.; Jiang, H.; Wang, L.; Chen, X.; Wu, K.; Zhang, S.; Ma, S.; Xia, B. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol. Lett., 2017, 13(5), 3494-3500.
[http://dx.doi.org/10.3892/ol.2017.5878]
[90]
Wang, Z.; Pan, L.; Yu, H.; Wang, Y. The long non-coding RNA SNHG5 regulates gefitinib resistance in lung adenocarcinoma cells by targetting miR-377/CASP1 axis. Biosci. Rep., 2018, 38(4)
[http://dx.doi.org/10.1042/BSR20180400]
[91]
Zhang, W.; Cai, X.; Yu, J.; Lu, X.; Qian, Q.; Qian, W. Exosome-mediated transfer of lncRNA RP11838N2.4 promotes erlotinib resistance in non-small cell lung cancer. Int. J. Oncol., 2018, 53(2), 527-538.

Rights & Permissions Print Cite
Article Metrics
31
© 2024 Bentham Science Publishers | Privacy Policy